Publications by authors named "Z Y Xu-Monette"

Article Synopsis
  • Deficient DNA mismatch repair (dMMR) serves as a biomarker indicating a better response to PD-1 blockade immunotherapy in solid tumors, including diffuse large B-cell lymphoma (DLBCL).
  • In a study involving a large cohort of DLBCL patients, genetic dMMR was found infrequently and linked to a more favorable immune microenvironment but did not show a strong prognostic impact.
  • Additionally, while phenotypic dMMR was also rare, its presence correlated with increased T cell activity, suggesting that PD-1 T cells may selectively target tumor cell subsets with dMMR, which has implications for the efficacy of immunotherapy in DLBCL.
View Article and Find Full Text PDF

Introduction: Our previous studies have demonstrated that tumor-infiltrating lymphocytes (TILs), including normal B cells, T cells, and natural killer (NK) cells, in diffuse large B-cell lymphoma (DLBCL) have a significantly favorable impact on the clinical outcomes of patients treated with standard chemoimmunotherapy. In this study, to gain a full overview of the tumor immune microenvironment (TIME), we assembled a flow cytometry cohort of 102 patients diagnosed with DLBCL at the Duke University Medical Center.

Methods: We collected diagnostic flow cytometry data, including the proportion of T cells, abnormal B cells, normal B cells, plasma cells, NK cells, monocytes, and granulocytes in fresh biopsy tissues at clinical presentation, and analyzed the correlations with patient survival and between different cell populations.

View Article and Find Full Text PDF

Lymphoma is the sixth most common type of cancer worldwide. Under the current treatment standards, patients with lymphoma often fail to respond to treatment or relapse early and require further therapy. Hence, novel therapeutic strategies need to be explored and our understanding of the molecular underpinnings of lymphomas should be expanded.

View Article and Find Full Text PDF
Article Synopsis
  • * Analyzing data from 269 DLBCL patients, the researchers found that higher TIL-B abundance correlates with better patient survival and distinct gene expression profiles, indicating a strong association with positive immune responses.
  • * The findings suggest that TIL-B frequency serves as a robust prognostic biomarker, exceeding previous classifications, and highlights the importance of TIL-Bs in guiding DLBCL treatment strategies.
View Article and Find Full Text PDF